Comparative Pharmacology
Head-to-head clinical analysis: ANTURANE versus PROBENECID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTURANE versus PROBENECID.
ANTURANE vs PROBENECID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).
200-400 mg orally twice daily
Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Clinical Note
moderateProbenecid + Torasemide
"The risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide."
Clinical Note
moderateProbenecid + Etacrynic acid
"The risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid."
Clinical Note
moderateProbenecid + Furosemide
"The risk or severity of adverse effects can be increased when Probenecid is combined with Furosemide."
Clinical Note
moderateProbenecid + Bumetanide
Terminal elimination half-life is approximately 6-12 hours in adults with normal renal function; may be prolonged in renal impairment or older adults.
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Renal excretion of unchanged drug and metabolites; ~77% of dose recovered in urine within 48 hours (50% as glucuronide conjugates, 27% as unchanged probenecid); ~11% excreted in feces via biliary elimination.
Category C
Category A/B
Uricosuric
Uricosuric
"The risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide."